Roche has announced that it has received CE Mark for its Accu Chek® Solo micropump system. The company will initiate the pilot commercialisation phase for its innovative insulin delivery system in Austria, Poland, Switzerland and the UK in the coming weeks and is conducting a clinical study in several European countries.
The Accu-Chek Solo micropump system allows for convenience and personalisation in insulin pump therapy while contributing to a more targeted and effective diabetes management. It offers the functionalities of a traditional insulin pump alongside with the technological advancement of tube-free insulin delivery.
The system consists of two parts: a small, lightweight and semi-disposable insulin micropump and a fully-featured remote control incorporating blood glucose monitoring and bolus advice. The system provides bolus insulin dosing both from the remote control or directly from the pump as well as the option to detach and re-attach the pump without wasting insulin. In addition, the system connects to Roche Diabetes Care’s digital solutions such as the Accu-Chek Smart Pix system, providing decision and therapy support at the doctor’s office with a proven tool for efficient, effective and personalised diabetes management.
Roland Diggelmann, CEO Roche Diagnostics said, “This important milestone will enable us to further expand access to insulin pump therapy to those people with diabetes who can benefit most from this therapy option – so they can spend more time in their ideal target range and experience an improved quality of life. The new modular design of our Accu-Chek Solo micropump system responds to the needs of people with diabetes for more discretion and flexibility.”